TABLE 3: Reports mentioning comorbidities (number and percentage) among the deceased subjects.
Study | Number | Death due | Hypertensio | Rheumati | Hepatopath | Diabete | Other |
---|---|---|---|---|---|---|---|
of deaths | to comorbidit | n (%) | c (%) | y (%) | s (%) | (%) | |
y (%) | |||||||
Renault - 2007 | 203 | 40.4 | - | - | - | - | - |
Lemant - 2008 | 16 | 50.0 | - | - | 1(6.2) | 5(31.2) | COPD |
Tandale - 2009 | 26 | 38.4 | - | - | - | - | - |
Tournebize - 2009 | 2 | 50.0 | - | - | - | - | Myasthenia |
Kee - 2010 | 1 | 100.0 | - | - | - | - | - |
Sam - 2010 | 1 | 100.0 | 1(100.0) | - | - | - | Cardiac Failure |
Gaüzère - 2011 | 21 | 38.0 | - | - | - | - | score IGSII |
Gurav - 2012 | 3 | 100.0 | 1(33.3) | - | - | 1(33.3) | Ischemic heart disease |
Hertz - 2012 | 5 | 80.0 | - | - | - | 1(20.0) | Pleural effusion |
Hoz - 2015 | 3 | 33.0 | 1(33.3) | - | - | - | Benign prostatic hyperplasia |
Sharp - 2015 | 28 | 32.1 | 15(53.6) | - | - | 11(39.3) | Obesity; Sickle cell anemia; Chronic kidney disease; Leptospirosis |
Viasus - 2015 | 1 | 100.0 | - | - | - | - | - |
Betancur - 2016 | 1 | 100.0 | - | 1(100.0) | - | - | - |
López - 2016 | 2 | 100.0 | - | - | - | - | - |
Perti - 2016 | 6 | 33.3 | - | - | 1(16.7) | - | - |
Cardona-Ospina - 2018 | 1 | 100.0 | 1(100.0) | - | - | - | Chronic heart failure; Atrial fibrillation; Chronic venous disease; Right bundle branch block |
Colavita - 2018 | 1 | 100.0 | 1(100.0) | - | - | - | Ischemic heart disease; Chronic inferior limbs arteriopathy; Bilateral carotid atherosclerosis |
“-“: not informed; IGSII: indice de gravité simplifié.